Pfizer’s Talzenna PARP breast cancer drug approved in US

The US drug regulator has approved Pfizer’s breast cancer medicine Talzenna (talazoparib) for patients with a certain mutation. The drug was approved by the US Food and Drug Administration (FDA) for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer. Talzenna is a poly (ADP-ribose) polymerase (PARP) inhibitor and is the second drug of this class approved in breast cancer after AstraZeneca’s Lynparza (olaparib) earlier this year. It works by causing cancer cells to self-destruct by inhibiting their ability to fix damaged DNA.